CY1114880T1 - Αγωνιστες mglu2 - Google Patents
Αγωνιστες mglu2Info
- Publication number
- CY1114880T1 CY1114880T1 CY20131101012T CY131101012T CY1114880T1 CY 1114880 T1 CY1114880 T1 CY 1114880T1 CY 20131101012 T CY20131101012 T CY 20131101012T CY 131101012 T CY131101012 T CY 131101012T CY 1114880 T1 CY1114880 T1 CY 1114880T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mglu2 agonists
- mglu2
- agonists
- fighters
- schizophrenia
- Prior art date
Links
- 101001071429 Homo sapiens Metabotropic glutamate receptor 2 Proteins 0.000 title abstract 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
H παρούσα εφεύρεση παρέχει νέους αγωνιστές mGlu2 χρήσιμους για τη θεραπεία της διπολικής διαταραχής, της σχιζοφρένειας, της κατάθλιψης και της διαταραχής γενικευμένου άγχους. Οι νέοι αγωνιστές αντιπροσωπεύονται από τον τύπο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382290 | 2009-12-21 | ||
| US30523910P | 2010-02-17 | 2010-02-17 | |
| EP10798419.7A EP2516406B1 (en) | 2009-12-21 | 2010-12-15 | Mglu2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114880T1 true CY1114880T1 (el) | 2016-12-14 |
Family
ID=42026702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101012T CY1114880T1 (el) | 2009-12-21 | 2013-11-14 | Αγωνιστες mglu2 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8318184B2 (el) |
| EP (1) | EP2516406B1 (el) |
| JP (1) | JP5779190B2 (el) |
| KR (1) | KR101395356B1 (el) |
| CN (1) | CN102695701B (el) |
| AR (1) | AR079343A1 (el) |
| AU (1) | AU2010340039B2 (el) |
| BR (1) | BR112012017188B1 (el) |
| CA (1) | CA2784667C (el) |
| CR (1) | CR20120322A (el) |
| CY (1) | CY1114880T1 (el) |
| DK (1) | DK2516406T3 (el) |
| DO (1) | DOP2012000173A (el) |
| EA (1) | EA020229B1 (el) |
| EC (1) | ECSP12011989A (el) |
| ES (1) | ES2435651T3 (el) |
| HN (1) | HN2012001160A (el) |
| HR (1) | HRP20131052T1 (el) |
| IL (1) | IL220011A (el) |
| JO (1) | JO2978B1 (el) |
| MA (1) | MA33824B1 (el) |
| MX (1) | MX2012007332A (el) |
| MY (1) | MY160618A (el) |
| NZ (1) | NZ600305A (el) |
| PE (1) | PE20121688A1 (el) |
| PH (1) | PH12012501253A1 (el) |
| PL (1) | PL2516406T3 (el) |
| PT (1) | PT2516406E (el) |
| RS (1) | RS53063B (el) |
| SG (1) | SG181836A1 (el) |
| SI (1) | SI2516406T1 (el) |
| TN (1) | TN2012000281A1 (el) |
| TW (1) | TWI477490B (el) |
| UA (1) | UA107684C2 (el) |
| WO (1) | WO2011084437A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722660B2 (en) | 2010-02-17 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| KR101554793B1 (ko) * | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2／3 길항제로서의 4-치환된-3-벤질옥시-비시클로［3.1.0］헥산 화합물 |
| US9296710B2 (en) * | 2011-06-17 | 2016-03-29 | Eli Lilly And Company | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist |
| AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| AU2015208233B2 (en) * | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| PT3277270T (pt) | 2015-04-01 | 2021-12-07 | Akebia Therapeutics Inc | Composições e métodos de tratamento de anemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576323A (en) * | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| US7038077B2 (en) * | 2001-01-11 | 2006-05-02 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| IL156364A0 (en) * | 2001-01-11 | 2004-01-04 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| DE60325968D1 (de) * | 2002-06-11 | 2009-03-12 | Lilly Co Eli | Prodrugs von exzitatorischen aminosäuren |
| US7381746B2 (en) * | 2003-06-26 | 2008-06-03 | Taisho Pharmaceutical Co., Ltd. | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative |
| AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| KR101554793B1 (ko) * | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2／3 길항제로서의 4-치환된-3-벤질옥시-비시클로［3.1.0］헥산 화합물 |
-
2010
- 2010-12-09 AR ARP100104553A patent/AR079343A1/es active IP Right Grant
- 2010-12-09 JO JO2010439A patent/JO2978B1/en active
- 2010-12-10 TW TW099143362A patent/TWI477490B/zh active
- 2010-12-15 PT PT107984197T patent/PT2516406E/pt unknown
- 2010-12-15 HR HRP20131052AT patent/HRP20131052T1/hr unknown
- 2010-12-15 PE PE2012000856A patent/PE20121688A1/es active IP Right Grant
- 2010-12-15 DK DK10798419.7T patent/DK2516406T3/da active
- 2010-12-15 NZ NZ600305A patent/NZ600305A/en unknown
- 2010-12-15 JP JP2012544727A patent/JP5779190B2/ja active Active
- 2010-12-15 BR BR112012017188-7A patent/BR112012017188B1/pt active IP Right Grant
- 2010-12-15 US US12/968,352 patent/US8318184B2/en active Active
- 2010-12-15 PL PL10798419T patent/PL2516406T3/pl unknown
- 2010-12-15 PH PH1/2012/501253A patent/PH12012501253A1/en unknown
- 2010-12-15 EP EP10798419.7A patent/EP2516406B1/en active Active
- 2010-12-15 MX MX2012007332A patent/MX2012007332A/es active IP Right Grant
- 2010-12-15 CA CA2784667A patent/CA2784667C/en active Active
- 2010-12-15 UA UAA201206909A patent/UA107684C2/ru unknown
- 2010-12-15 EA EA201290558A patent/EA020229B1/ru not_active IP Right Cessation
- 2010-12-15 CN CN201080058183.2A patent/CN102695701B/zh active Active
- 2010-12-15 ES ES10798419T patent/ES2435651T3/es active Active
- 2010-12-15 AU AU2010340039A patent/AU2010340039B2/en active Active
- 2010-12-15 WO PCT/US2010/060371 patent/WO2011084437A1/en not_active Ceased
- 2010-12-15 RS RS20130530A patent/RS53063B/sr unknown
- 2010-12-15 SI SI201030387T patent/SI2516406T1/sl unknown
- 2010-12-15 MY MYPI2012002794A patent/MY160618A/en unknown
- 2010-12-15 KR KR1020127015935A patent/KR101395356B1/ko active Active
- 2010-12-15 SG SG2012045563A patent/SG181836A1/en unknown
-
2012
- 2012-05-24 IL IL220011A patent/IL220011A/en active IP Right Grant
- 2012-05-30 HN HN2012001160A patent/HN2012001160A/es unknown
- 2012-06-01 TN TNP2012000281A patent/TN2012000281A1/en unknown
- 2012-06-13 CR CR20120322A patent/CR20120322A/es unknown
- 2012-06-14 MA MA34967A patent/MA33824B1/fr unknown
- 2012-06-19 DO DO2012000173A patent/DOP2012000173A/es unknown
- 2012-06-20 EC ECSP12011989 patent/ECSP12011989A/es unknown
-
2013
- 2013-11-14 CY CY20131101012T patent/CY1114880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114880T1 (el) | Αγωνιστες mglu2 | |
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| CY1118250T1 (el) | Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων | |
| UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO6241120A2 (es) | (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS. | |
| UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
| BRPI0814772A2 (pt) | Indazóis substituídos por 5-piridinona | |
| CR11814A (es) | Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica | |
| MY143269A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder | |
| ECSP11011021A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| CR20120362A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| RU2011135537A (ru) | Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов | |
| JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
| ATE506385T1 (de) | Nanoharnstoff-dispersionen | |
| UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. | |
| EA201000069A1 (ru) | Новые гербициды | |
| CL2008001837A1 (es) | Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia. | |
| EA200701592A1 (ru) | Композиты и способы их получения и использования | |
| CR20110361A (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif | |
| CL2009000257A1 (es) | Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico. | |
| CO7160067A2 (es) | Formulaciones de agonistas del receptor de somatostatina |